Stay ahead with the latest industry news in the GLP-1 sector and various downstream markets.
Thank you! You're all set—look out for the latest updates in your inbox soon!
Oops! Something went wrong.
No strings attached. Unsubscribe anytime. For further details, review our Privacy Policy.
Join 1.500+ professionals from pharma, medtech, CPG, food, finance, tech and other industries, staying in the loop with the latest GLP-1 updates and insights.
Pharma & Biotech
Wegovy approved in the US for cardiovascular risk reduction
8 Mar, 2024 Novo Nordisk today announced that the FDA has approved a label expansion for Wegovy to reduce risks of major adverse cardiovascular events in adults with either overweight or obesity and established cardiovascular disease.
Vivani stock soars 385% after citing positive preclinical weight loss data
28 Feb, 2024 Vivani Medical today announced positive preclinical data on weight loss effects for NPM-115, its miniature, twice-yearly, exenatide implant under development. Vivani also disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139, a subdermal GLP-1 implant in development, with the added potential benefit of once-yearly administration.
Viking Therapeutics reports positive trial results for GLP-1/GIP agonist
27 Feb, 2024 Viking Therapeutics today announced results from its VENTURE phase 2 trial of VK2735, showing significant weight loss in patients compared to placebo. The study also indicated that VK2735 was safe, with the majority of gastrointestinal side effects being mild or moderate.
Boehringer Ingelheim's glucagon/GLP-1 agonist reduces MASH in trial
26 Feb, 2024 Boehringer Ingelheim revealed new phase 2 data for Zealand Pharma-partnered survodutide, a dual GLP-1/glucagon receptor agonist candidate, showing significant improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Indian pharma companies developing GLP-1 versions
22 Feb, 2024 Indian drugmakers including Sun Pharma, Cipla, Dr. Reddy's and Lupin have begun developing their own versions of GLP-1 drugs, taking the generic path (Cipla, Dr. Reddy's and Lupin) or working on its own drug (Sun Pharma).
EU to review Lilly’s multi-dose pen for Mounjaro
19 Feb, 2024 An EMA committee is scheduled to decide on extending the market authorization for Eli Lilly’s Mounjaro (tirzepatide) to include its multi-dose, pre-filled KwikPen, according to a draft agenda of its upcoming meetings.
MedTech
GLP-1 wave leaves room for dialysis, Fresenius Medical says
21 Feb, 2024 FMC CEO Helen Giza expects a net benefit for dialysis companies from the GLP-1 wave: if GLP-1 treatments can prevent heart attacks and strokes, more patients will go on dialysis.
HealthTech
9amHealth raises $9.5M led by Cigna
20 Feb, 2024 Virtual cardiometabolic care provider 9amHealth has raised $9.5 million in a Series A extension led by Cigna, aiming to broaden its services to employers across the U.S., in response to the high demand for GLP-1 medications.
Omada expands GLP-1 program to prioritize muscle restoration
13 Feb, 2024 The expanded GLP-1 Care Track will connect customers with a care team and physical therapists to help patients regain muscle mass after stopping GLP-1 drug usage.
Patientory Wallet launches telehealth service for GLP-1
7 Feb, 2024 Healthcare data startup Patientory introduces a new telehealth service for weight loss using GLP-1 medications, combining a prescription of Semaglutide with coaching.
Insurance
Elevance launches weight management program with GLP-1 support
26 Feb, 2024 Elevance Health's CarelonRx will begin offering a weight management program, providing its members access to digital-first coaching and wellness tools. Users who are prescribed GLP-1 drugs will have access to medication management support and a digital companion module.
General
Researchers leverage AI to identify potential plant-based GLP-1 agonists
29 Mar, 2024 Drawing on recent understanding around the synthetic compounds TTOAD2 and orforglipron, Spanish researchers used AI to identify alternative natural-derived compounds. Details will be presented at ECO 2024 in May.
GLP-1s could boost US GDP by 1% in coming years
22 Feb, 2024 According to Goldman Sachs, the widespread use of GLP-1 drugs in the United States could boost gross domestic product by 1% in the coming years, as lower obesity-related complications are likely to boost workplace efficiency.
Food
GLP-1 gives Sweetgreen a boost, survey finds
21 Feb, 2024 According to a 300-person survey, people reported going to Sweetgreen more frequently after starting GLP-1 medications. It was the only restaurant in the survey that saw a net increase in frequency of visits from those taking the shots.
Conagra sees opportunity to sell more frozen meals to GLP-1 patients
21 Feb, 2024 U.S. packaged foods firm Conagra Brands sees an opportunity to sell more frozen meals and snacks to people taking GLP-1 drugs. According to executive Tom McGough, market research shows that consumption of "better-for-you" frozen meals increases 8% among people taking GLP-1s.
Daily Harvest introduces GLP-1 focused meal plans
8 Jan, 2024 Recognizing the critical role of diet in complementing the weight management journey of GLP-1 medication users, Daily Harvest has launched the GLP-1 Companion Food Collection.
VMS & Diets
Genesis Supplements launches probiotic supplement to enhance the effects of GLP-1 therapies
16 Feb, 2024 Genesis is about to launch Korbiotic, a probiotic GLP-1 support supplement aiming to help control blood sugar levels.
Herbalife launches GLP-1 companion product combos
8 Feb, 2024 Herbalife launches the Herbalife GLP-1 Nutrition Companion, a new range of food and supplement product combos intended to support the nutritional needs of individuals on GLP-1 medications.
Abbott launches new protein shake for people on GLP-1 drugs
31 Jan, 2024 The new PROTALITY brand targets people on GLP-1 drugs who may have difficulty getting enough protein and other essential nutrients to support muscle mass and function.
Zen Nutrients to offer GLP-1 support vitamin in 7.400 pharmacies
29 Nov, 2023 Zen Nutrients partners with Real Value Products to offer PeptideVite™ in both retail and specialty pharmacies, as well as physician and weight loss clinics.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
